Trials / Unknown
UnknownNCT02027090
High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
We hypothesize that higher dose icotinib is related with better efficacy. The primary objective is to compare the progression-free survival of higher dose and routine dose of icotinib in treating pretreated advanced non-small cell lung cancer patients with stable disease after 8-week routine dose icotinib treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Routine dose icotinib | Icotinib is administered 125 mg three times daily. |
| DRUG | Higher dose icotinib | After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-06-01
- Completion
- 2016-12-01
- First posted
- 2014-01-03
- Last updated
- 2015-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02027090. Inclusion in this directory is not an endorsement.